Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IPCALAB.NS Stock Summary
Top 10 Correlated ETFs
IPCALAB.NS
In the News
IPCALAB.NS Financial details
Company Rating
Buy
Market Cap
198.62B
Income
5.25B
Revenue
60.22B
Book val./share
-
Cash/share
-
Dividend
4
Dividend %
0.51%
Employees
15.16K
Optionable
No
Shortable
Yes
Earnings
16 Feb 2023
P/E
37.87
Forward P/E
6.37
PEG
-7.01
P/S
3.3
P/B
3.44
P/C
-
P/FCF
-
Quick Ratio
1.05
Current Ratio
3.29
Debt / Equity
-
LT Debt / Equity
0.08
-
-
EPS (TTM)
20.69
EPS next Y
122.89
EPS next Q
-
EPS this Y
-22.45%
EPS next Y
493.84%
EPS next 5Y
591.5%
EPS last 5Y
29.77%
Revenue last 5Y
12.7%
Revenue Q/Q
-3.43%
EPS Q/Q
-25.04%
-
-
-
-
SMA20
-7%
SMA50
-8.3%
SMA100
-13.75%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
9%
ROC
0.11%
Gross Margin
64%
Oper. Margin
12%
Profit Margin
9%
Payout
-
Shs Outstand
253.7M
Shs Float
130.4M
-
-
-
-
Target Price
-
52W Range
767.5-1095.0
52W High
-28.51%
52W Low
+2.07%
RSI
33
Rel Volume
0.25
Avg Volume
290.95K
Volume
73.71K
Perf Week
-1.44%
Perf Month
-9.04%
Perf Quarter
-12.59%
Perf Half Y
-8.81%
-
-
-
-
Beta
0.151742
-
-
Volatility
3.67%, 30%
Prev Close
0.38%
Price
782.85
Change
-0.29%
IPCALAB.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-31
Metric | History | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 127.04 | 146.14 | 180.4 | 210.87 | 230.17 | |
Net income per share | 9.49 | 17.61 | 23.99 | 45.01 | 34.91 | |
Operating cash flow per share | 13.52 | 19.48 | 22.33 | 43.04 | 33.8 | |
Free cash flow per share | 8.1 | 12.34 | 10.21 | 28.77 | 14.89 | |
Cash per share | 8.66 | 14.71 | 16.54 | 29.91 | 58.89 | |
Book value per share | 106.52 | 123.58 | 143.55 | 185.63 | 216.83 | |
Tangible book value per share | 101.35 | 115.33 | 136.22 | 179.86 | 211.13 | |
Share holders equity per share | 106.52 | 123.58 | 143.55 | 185.63 | 216.83 | |
Interest debt per share | 25.79 | 19.13 | 20.44 | 10.82 | 32.17 | |
Market cap | 83.93B | 122.88B | 175.91B | 241.09B | 269.93B | |
Enterprise value | 88.71B | 124.72B | 180.34B | 242.08B | 275.25B | |
P/E ratio | 35.06 | 27.62 | 29.01 | 21.15 | 30.53 | |
Price to sales ratio | 2.62 | 3.33 | 3.86 | 4.51 | 4.63 | |
POCF ratio | 24.6 | 24.96 | 31.18 | 22.12 | 31.53 | |
PFCF ratio | 41.06 | 39.42 | 68.19 | 33.09 | 71.58 | |
P/B Ratio | 3.12 | 3.94 | 4.85 | 5.13 | 4.92 | |
PTB ratio | 3.12 | 3.94 | 4.85 | 5.13 | 4.92 | |
EV to sales | 2.77 | 3.38 | 3.96 | 4.53 | 4.72 | |
Enterprise value over EBITDA | 18.04 | 16.63 | 18.63 | 15.15 | 20.4 | |
EV to operating cash flow | 26.01 | 25.34 | 31.96 | 22.21 | 32.15 | |
EV to free cash flow | 43.4 | 40.01 | 69.9 | 33.23 | 72.99 | |
Earnings yield | 0.03 | 0.04 | 0.03 | 0.05 | 0.03 | |
Free cash flow yield | 0.02 | 0.03 | 0.01 | 0.03 | 0.01 | |
Debt to equity | 0.53 | 0.45 | 0.45 | 0.29 | 0.38 | |
Debt to assets | 0.35 | 0.31 | 0.31 | 0.22 | 0.27 | |
Net debt to EBITDA | 0.97 | 0.25 | 0.46 | 0.06 | 0.39 | |
Current ratio | 1.93 | 2.17 | 2.15 | 3.03 | 3.04 | |
Interest coverage | 12.1 | 29.24 | 47.01 | 153.37 | 140.03 | |
Income quality | 1.42 | 1.11 | 0.93 | 0.96 | 0.97 | |
Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
Payout ratio | 0.06 | 0.03 | 0.2 | 0.09 | 0.11 | |
Sales general and administrative to revenue | 0.02 | 0.02 | 0.01 | 0.02 | 0 | |
Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
Intangibles to total assets | 0.03 | 0.05 | 0.04 | 0.03 | 0.03 | |
Capex to operating cash flow | -0.4 | -0.37 | -0.54 | -0.33 | -0.56 | |
Capex to revenue | -0.04 | -0.05 | -0.07 | -0.07 | -0.08 | |
Capex to depreciation | -0.77 | -0.99 | -1.46 | -1.73 | -2.06 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 150.78 | 221.26 | 278.38 | 433.58 | 412.67 | |
ROIC | 0.07 | 0.12 | 0.13 | 0.22 | 0.13 | |
Return on tangible assets | 0.06 | 0.1 | 0.12 | 0.19 | 0.12 | |
Graham Net | -30.5 | -19.99 | -21.34 | 8.01 | 13.84 | |
Working capital | 9.38B | 12.8B | 15.29B | 23.04B | 29.91B | |
Tangible asset value | 25.58B | 29.14B | 34.42B | 45.55B | 53.48B | |
Net current asset value | 5.17B | 9.65B | 12.37B | 20.85B | 23.87B | |
Invested capital | 0.23 | 0.15 | 0.14 | 0.06 | 0.15 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 4.41B | 4.74B | 5.67B | 6.38B | 6.12B | |
Average inventory | 8.81B | 9.77B | 11.98B | 14.59B | 17.26B | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 131.41 | 148.31 | 130.26 | 134.95 | 101.03 | |
Days of inventory on hand | 273.26 | 303.37 | 282.61 | 323.08 | 336.58 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 2.78 | 2.46 | 2.8 | 2.7 | 3.61 | |
Inventory turnover | 1.34 | 1.2 | 1.29 | 1.13 | 1.08 | |
ROE | 0.09 | 0.14 | 0.17 | 0.24 | 0.16 | |
Capex per share | -5.42 | -7.15 | -12.12 | -14.27 | -18.91 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q3
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 56.38 | 50.81 | 62.52 | 63.08 | 60.93 | |
Net income per share | 7.76 | 5.13 | 5.64 | 5.67 | 4.25 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 58.79 | 0 | 57.41 | 0 | |
Book value per share | 0 | 216.47 | 0 | 227.67 | 0 | |
Tangible book value per share | 0 | 210.78 | 0 | 221.92 | 0 | |
Share holders equity per share | 0 | 216.47 | 0 | 227.67 | 0 | |
Interest debt per share | 0 | 31.95 | 0 | 29.28 | 0 | |
Market cap | 274.86B | 270.39B | 227.65B | 232.22B | 213.93B | |
Enterprise value | 0 | 275.71B | 0 | 235.69B | 0 | |
P/E ratio | 34.89 | 51.91 | 39.78 | 40.34 | 49.59 | |
Price to sales ratio | 19.21 | 20.97 | 14.36 | 14.51 | 13.84 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0 | 4.92 | 0 | 4.02 | 0 | |
PTB ratio | 0 | 4.92 | 0 | 4.02 | 0 | |
EV to sales | 0 | 21.39 | 0 | 14.72 | 0 | |
Enterprise value over EBITDA | 0 | 123.46 | 0 | 80.18 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0.38 | 0 | 0.35 | 0 | |
Debt to assets | 0 | 0.27 | 0 | 0.26 | 0 | |
Net debt to EBITDA | 0 | 2.38 | 0 | 1.18 | 0 | |
Current ratio | 0 | 3.04 | 0 | 3.29 | 0 | |
Interest coverage | 174.24 | 46.86 | 29.9 | 21.15 | 13.77 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.03 | 0 | 0.03 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 158.12 | 0 | 170.42 | 0 | |
ROIC | 0 | 0.02 | 0 | 0.02 | 0 | |
Return on tangible assets | 0 | 0.02 | 0 | 0.02 | 0 | |
Graham Net | 0 | 13.82 | 0 | 12.99 | 0 | |
Working capital | 0 | 29.91B | 0 | 31.7B | 0 | |
Tangible asset value | 0 | 53.48B | 0 | 56.32B | 0 | |
Net current asset value | 0 | 23.87B | 0 | 25.15B | 0 | |
Invested capital | 0 | 0.15 | 0 | 0.13 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 117.77 | 0 | 90.25 | 0 | |
Days of inventory on hand | 0 | 392.34 | 0 | 285.49 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.76 | 0 | 1 | 0 | |
Inventory turnover | 0 | 0.23 | 0 | 0.32 | 0 | |
ROE | 0 | 0.02 | 0 | 0.02 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
IPCALAB.NS Frequently Asked Questions
What is Ipca Laboratories Limited stock symbol ?
Ipca Laboratories Limited is a IN stock and trading under the symbol IPCALAB.NS
What is Ipca Laboratories Limited stock quote today ?
Ipca Laboratories Limited stock price is $782.85 today.
Is Ipca Laboratories Limited stock public?
Yes, Ipca Laboratories Limited is a publicly traded company.